A Prospective, Real‐World, Clinical Pharmacokinetic Study to Inform Lacosamide Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE‐02)

Author(s):  
Shamir N. Kalaria ◽  
Michael Armahizer ◽  
Paul McCarthy ◽  
Neeraj Badjatia ◽  
Jogarao V. Gobburu ◽  
...  
2011 ◽  
Vol 33 (4) ◽  
pp. 393-397 ◽  
Author(s):  
Jaroslav Radej ◽  
Ales Krouzecky ◽  
Pavel Stehlik ◽  
Roman Sykora ◽  
Jiri Chvojka ◽  
...  

2020 ◽  
Vol 49 (5) ◽  
pp. 622-626
Author(s):  
Huub L.A. van den Oever ◽  
Marieke Zeeman ◽  
Polina Nassikovker ◽  
Carmen Bles ◽  
Fred A.L. van Steveninck ◽  
...  

Background: Clonidine is an α2-agonist that is commonly used for sedation in the intensive care unit. When patients are on continuous venovenous hemofiltration (CVVH) in the presence of kidney dysfunction, the sieving coefficient of clonidine is required to estimate how much drug is removed by CVVH. In the present study, we measured the sieving coefficient of clonidine in critically ill, ventilated patients receiving CVVH. Methods: A total of 20 samples of plasma and ultrafiltrate of 3 patients on CVVH, using a standard 1.5 m2 polyacrylonitrile AN69 membrane, during continuous clonidine infusion were collected. After correction for the effect of predilution, we calculated the sieving coefficient for clonidine. Results: The mean sieving coefficient of clonidine was 0.52 (SD 0.097). Conclusion: Using a polyacrylonitrile AN69 membrane in a CVVH machine, the in vivo sieving coefficient of clonidine was 0.52.


1998 ◽  
Vol 26 (1) ◽  
pp. 88-91 ◽  
Author(s):  
Gilles Capellier ◽  
Christian Cornette ◽  
Annie Boillot ◽  
Christiane Guinchard ◽  
Thierry Jacques ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document